One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

A. A.M. van der Veldt; S. F. Oosting; R. S.N. Fehrmann; C. H. GeurtsvanKessel; R. S. van Binnendijk; A. M.C. Dingemans; E. F. Smit; T. J.N. Hiltermann; G. den Hartog; M. Jalving; T. T. Westphal; A. Bhattacharya; F. de Wilt; S. M. Ernst; A. Boerma; L. van Zijl; G. F. Rimmelzwaan; P. Kvistborg; C. A.C.M. van Els; N. Y. Rots; D. van Baarle; J. B.A.G. Haanen; E. G.E. de Vries

doi:10.1016/j.esmoop.2023.100785

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

A. A.M. van der Veldt^*, S. F. Oosting, R. S.N. Fehrmann, C. H. GeurtsvanKessel, R. S. van Binnendijk, A. M.C. Dingemans, E. F. Smit, T. J.N. Hiltermann, G. den Hartog, M. Jalving, T. T. Westphal, A. Bhattacharya, F. de Wilt, S. M. Ernst, A. Boerma, L. van Zijl, G. F. Rimmelzwaan, P. Kvistborg, C. A.C.M. van Els, N. Y. RotsD. van Baarle, J. B.A.G. Haanen, E. G.E. de Vries

^*Corresponding author for this work

Translational Immunology Groningen (TRIGR)

Research output: Contribution to journal › Letter › Academic › peer-review

2 Citations (Scopus)

73 Downloads (Pure)

Original language	English
Article number	100785
Number of pages	2
Journal	ESMO Open
Volume	8
Issue number	1
DOIs	https://doi.org/10.1016/j.esmoop.2023.100785
Publication status	Published - Feb-2023

Access to Document

10.1016/j.esmoop.2023.100785Licence: CC BY-NC-ND

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatmentFinal publisher's version, 3.62 MBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

van der Veldt, A. A. M., Oosting, S. F., Fehrmann, R. S. N., GeurtsvanKessel, C. H., van Binnendijk, R. S., Dingemans, A. M. C., Smit, E. F., Hiltermann, T. J. N., Hartog, G. D., Jalving, M., Westphal, T. T., Bhattacharya, A., de Wilt, F., Ernst, S. M., Boerma, A., van Zijl, L., Rimmelzwaan, G. F., Kvistborg, P., van Els, C. A. C. M., ... de Vries, E. G. E. (2023). One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment. ESMO Open, 8(1), Article 100785. https://doi.org/10.1016/j.esmoop.2023.100785

@article{c390d6c857b14e21b9aca366c86e9e32,

title = "One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment",

author = "{van der Veldt}, {A. A.M.} and Oosting, {S. F.} and Fehrmann, {R. S.N.} and GeurtsvanKessel, {C. H.} and {van Binnendijk}, {R. S.} and Dingemans, {A. M.C.} and Smit, {E. F.} and Hiltermann, {T. J.N.} and Hartog, {G. den} and M. Jalving and Westphal, {T. T.} and A. Bhattacharya and {de Wilt}, F. and Ernst, {S. M.} and A. Boerma and {van Zijl}, L. and Rimmelzwaan, {G. F.} and P. Kvistborg and {van Els}, {C. A.C.M.} and Rots, {N. Y.} and {van Baarle}, D. and Haanen, {J. B.A.G.} and {de Vries}, {E. G.E.}",

note = "Funding Information: The study is funded by ZonMw , the Netherlands Organisation for Health Research and Development . Funding Information: AAMvdV reports consultancy fees from BMS, Merck Sharp & Dohme (MSD), Merck, Sanofi, Eisai, Pfizer, Ipsen, Roche, Pierre Fabre, and Novartis; and travel support from Bayer, Roche, Novartis, and Pfizer (all paid to the institution). SFO reports research grants from Novartis and Celldex Therapeutics; and consultancy fees from Genmab, Merck, and Bristol Myers Squibb (BMS; all paid to the institution). AMCD reports consultancy fees from Roche, Boehringer Ingelheim, Amgen, Bayer, PharmaMar, Sanofi, and Daiichi (all paid to the institution); speaker fees from Eli Lilly, AstraZeneca, Jansen, Chiesi, and Takeda (all paid to the institution); and research support from BMS, AbbVie, and Amgen (all paid to the institution). EFS reports consultancy fees from Eli Lilly (all paid to the institution); speaker fees from AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo (all paid to the institution); and advisory board fees from AstraZeneca, Bayer, BMS, MSD, Merck, Novartis, Pfizer, Roche Genentech, Roche Diagnostics, and Takeda (all paid to the institution). TJNH reports advisory board fees from BMS, AstraZeneca, Merck, Pfizer, Roche, and MSD (all paid to the institution). MJ reports consultancy fees from AstraZeneca and Pierre Fabre (all paid to the institution). GFR reports funding from the Alexander von Humboldt Foundation (paid to the institution). JBAGH reports consultancy fees from Achilles Therapeutics, BioNTech, BMS, Immunocore, Instil Bio, Molecular Partners, MSD, Gadeta, Merck Serono, Neogene Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene Tx; speaker fees from Ipsen, Eisai, and Novartis (paid to the institution); research grants from Asher-Bio, BMS, BioNTech, MSD, and Novartis (paid to the institution); and stock in Neogene Tx. EGEdV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi; and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (all paid to the institution). All other authors have declared no conflicts of interest. ",

year = "2023",

month = feb,

doi = "10.1016/j.esmoop.2023.100785",

language = "English",

volume = "8",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "BMJ Publishing Group",

number = "1",

}

van der Veldt, AAM, Oosting, SF , Fehrmann, RSN, GeurtsvanKessel, CH, van Binnendijk, RS, Dingemans, AMC, Smit, EF, Hiltermann, TJN, Hartog, GD, Jalving, M, Westphal, TT, Bhattacharya, A, de Wilt, F, Ernst, SM, Boerma, A, van Zijl, L, Rimmelzwaan, GF, Kvistborg, P, van Els, CACM, Rots, NY, van Baarle, D, Haanen, JBAG & de Vries, EGE 2023, 'One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment', ESMO Open, vol. 8, no. 1, 100785. https://doi.org/10.1016/j.esmoop.2023.100785

TY - JOUR

T1 - One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment

AU - van der Veldt, A. A.M.

AU - Oosting, S. F.

AU - Fehrmann, R. S.N.

AU - GeurtsvanKessel, C. H.

AU - van Binnendijk, R. S.

AU - Dingemans, A. M.C.

AU - Smit, E. F.

AU - Hiltermann, T. J.N.

AU - Hartog, G. den

AU - Jalving, M.

AU - Westphal, T. T.

AU - Bhattacharya, A.

AU - de Wilt, F.

AU - Ernst, S. M.

AU - Boerma, A.

AU - van Zijl, L.

AU - Rimmelzwaan, G. F.

AU - Kvistborg, P.

AU - van Els, C. A.C.M.

AU - Rots, N. Y.

AU - van Baarle, D.

AU - Haanen, J. B.A.G.

AU - de Vries, E. G.E.

N1 - Funding Information: The study is funded by ZonMw , the Netherlands Organisation for Health Research and Development . Funding Information: AAMvdV reports consultancy fees from BMS, Merck Sharp & Dohme (MSD), Merck, Sanofi, Eisai, Pfizer, Ipsen, Roche, Pierre Fabre, and Novartis; and travel support from Bayer, Roche, Novartis, and Pfizer (all paid to the institution). SFO reports research grants from Novartis and Celldex Therapeutics; and consultancy fees from Genmab, Merck, and Bristol Myers Squibb (BMS; all paid to the institution). AMCD reports consultancy fees from Roche, Boehringer Ingelheim, Amgen, Bayer, PharmaMar, Sanofi, and Daiichi (all paid to the institution); speaker fees from Eli Lilly, AstraZeneca, Jansen, Chiesi, and Takeda (all paid to the institution); and research support from BMS, AbbVie, and Amgen (all paid to the institution). EFS reports consultancy fees from Eli Lilly (all paid to the institution); speaker fees from AstraZeneca, Boehringer Ingelheim, and Daiichi Sankyo (all paid to the institution); and advisory board fees from AstraZeneca, Bayer, BMS, MSD, Merck, Novartis, Pfizer, Roche Genentech, Roche Diagnostics, and Takeda (all paid to the institution). TJNH reports advisory board fees from BMS, AstraZeneca, Merck, Pfizer, Roche, and MSD (all paid to the institution). MJ reports consultancy fees from AstraZeneca and Pierre Fabre (all paid to the institution). GFR reports funding from the Alexander von Humboldt Foundation (paid to the institution). JBAGH reports consultancy fees from Achilles Therapeutics, BioNTech, BMS, Immunocore, Instil Bio, Molecular Partners, MSD, Gadeta, Merck Serono, Neogene Therapeutics, Novartis, Pfizer, PokeAcel, Roche/Genentech, Sanofi, and T-Knife (paid to the institution); consultancy fees from Neogene Tx; speaker fees from Ipsen, Eisai, and Novartis (paid to the institution); research grants from Asher-Bio, BMS, BioNTech, MSD, and Novartis (paid to the institution); and stock in Neogene Tx. EGEdV reports an advisory role at Daiichi Sankyo, NSABP, and Sanofi; and research funding from Amgen, AstraZeneca, Bayer, Chugai Pharma, Crescendo, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, Servier, and Synthon (all paid to the institution). All other authors have declared no conflicts of interest.

PY - 2023/2

Y1 - 2023/2

U2 - 10.1016/j.esmoop.2023.100785

DO - 10.1016/j.esmoop.2023.100785

M3 - Letter

C2 - 36764094

AN - SCOPUS:85147817467

SN - 2059-7029

VL - 8

JO - ESMO Open

JF - ESMO Open

IS - 1

M1 - 100785

ER -